Abstract 108P
Background
The human epidermal growth factor receptor 2 (HER2/neu) play a predictive and prognostic role in colorectal cancer (CRC). Accurate evaluating of HER2 overexpression is required for selection and determination of eligible patients for HER2-directed therapy or primary resistance and poor response to anti-EGFR therapy. However, there is no currently established best practice for HER2 testing and interpretation in CRC. The purpose of this study was to validate and evaluate the performance of AmoyDx® HANDLE Classic NGS Panel (CP40) in assessing HER2 status by comparing it with HER2 IHC (4B5)/FISH analysis.
Methods
The CP40 is based on Halo-shape ANnealing and Defer-Ligation Enrichment (HANDLE) system technology, which allows high sensitivity in 40 key solid tumour genes qualitative detection and microsatellite instability (MSI) status assessment utilizing DNA and RNA. Performance of the CP40 was compared against the HER2 IHC/FISH assay according to the HERACLES scoring criteria using 805 CRC samples. Only samples with a ratio ERBB2:CEN17 ≥ 2 or staining equivocal (2+) or positive (3+) in at least 50% of cells were determined as HER2 IHC/FISH positive.
Results
CP40 and IHC/FISH assays were highly concordant in their assessment of HER2 status in CRCs (99.50%, 801/805, kappa = 0.892). Three conflicting results were negative in CP40 but were scored 2+ in 50-70% of the cells and identified as positive by IHC/FISH. One CRC scored as 3+ in 40% cells was determined to be negative by both CP40 and IHC/FISH. And all MSI CRCs were evaluated as HER2 negative by both CP40 and IHC. Table: 108P
Comparison of HER2 status determined from CP40 and IHC/FISH assays
ERBB2 NGS-based CNV testing | ||||
True | False | Total | ||
HER2 IHC/FISH assay | Positive | 17 | 3 | 20 |
Negative | 1 | 784 | 785 | |
Total | 18 | 787 | 805 | |
Kappa= | 0.892 | |||
Overall coincidence rate = | 99.50% |
Conclusions
CRC-specific HER2 testing protocols and HER2 scoring criteria still needs to be optimised in a more refined and defined manner. HANDLE-based CP40, which combines DNA and RNA in NGS testing, is a potent tool for sensitive and reliable detection of HER2 status in clinical diagnostics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract